PATENT CLAIM ANALYSIS

Application Number: 16018400
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-04
Patent Classification: ["424", "133100"]

Abstract:
The present disclosure relates to glycoproteins, particularly monoclonal antibodies, comprising a glycoengineered Fc region, wherein said Fc region comprises an optimized N-glycan having the structure of Sia 2 (α2-6)Gal 2 GlcNAc 2 Man 3 GlcNAc 2 . The glycoengineered Fc region binds FcγRIIA or FcγRIIIA with a greater affinity, relative to comparable monoclonal antibodies comprising the wild-type Fc region. The monoclonal antibodies of the invention are particularly useful in preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection where an enhanced efficacy of effector cell function (e.g., ADCC) mediated by FcγR is desired, e.g., cancer, autoimmune, infectious disease, and in enhancing the therapeutic efficacy of therapeutic antibodies the effect of which is mediated by ADCC.

Claim (Index 15):
A method for preventing, treating, or ameliorating one or more symptoms associated with a disease, disorder, or infection, the method comprising administering to a subject in need thereof a therapeutically effective amount of the pharmaceutical composition according to  claim 13 .

Metadata:
- Claim Count in Document: 14.0
- Percentile: 94.0
- Lexical Diversity: 1.775
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['14723181', '15011544', '16014255', '13811159', '16011622']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6240934905733714
- 35 USC 102 Novelty (BERT): 0.5358733790364899
- Combined Prediction Score: 0.6152714794196833
- Mean Citation Score: 351.57935
- Max Citation Score: 369.9033
- Similarity Product: 235.02817757415173

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test